GlobeNewswire

With the release of Version 7.1, Sciforma launches Connections, a smart feature providing a holistic view of the enterprise

Dela

Sciforma 7.1 brings new level of agility to digital transformation

 

SAN JOSE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Sciforma, a leading provider of Project and Portfolio Management (PPM) software for large and mid-size companies, announced today the latest version of its PPM solution: Sciforma 7.1. Representing a new generation in PPM systems connecting people, teams and project data, Sciforma 7.1 helps keep all stakeholders constantly aware of the overall context, so they can anticipate any disruptions that would impact goals and objectives.

For any project manager, managing unforeseen changes can be immensely challenging, even for Agile teams. Team members are often involved in multiple projects at the same time, which exposes the entire team to the difficulty of factoring in external elements. Yet, most PPM software continues treating project managers as if they were working in silos, ignoring what is happening elsewhere in their organizations.

With "Connections," Sciforma gives project, product and program managers instant visibility into their surroundings.  The potential impact of previous, ongoing or future initiatives from other parts of the organization can be constantly factored into planning.

"With Sciforma 7.1's new Connections feature, people, teams and project data are all interconnected," explains Fabien Herelle, Sciforma Vice President of Solutions. "Managers can very easily track a project's history and predict its course in both the technical and business contexts."

Dan Stang, Gartner Research VP, wrote, "Project management offices often struggle to set the right priorities and achieve the desired outcomes and value from their work efforts. As program and portfolio management leaders transform their PMOs to support digital, they should use an approach that ends with projects and starts with context." [1]

"CONNECTIONS" BENEFITS:

  • Identify any other business cases, projects, products or programs that share the same life cycle, budget goals or scope, so that they are systematically considered when changes to scope or dates are made.

  • Constantly visualize their environment in the greater context, so that interconnections and dependencies with other parts of the organization are taken into account when making decisions.

  • Leverage status reports to understand the status of any of those connected elements. Potential slips and associated risks can be anticipated and the right actors contacted, to enable everyone to adapt to upcoming changes.

  • Easily communicate through Notes with the other stakeholders.

  • Conduct program or product review meetings with dashboards consolidating and highlighting key elements from the connected projects.

  • Easily keep track of the arc of a project: why it was launched; the how and why of decisions made along the way; and the objectives agreed upon to stay on target.

WHAT'S NEW IN SCIFORMA 7.1? 

  • Stronger Multi-Methodologies Integration in Project Planning and Management: Project Managers can use the Sciforma solution to work either using Agile methodologies, more classic Waterfall approaches, critical chain, or other leading approaches - all at no additional cost.

  • New capabilities to create assessment and scoring templates tailored to the organization's needs in Idea Management.

  • New Resource Management techniques to allocate resources to projects, based on organization's maturity.

  • New Budget-driven Ranking and drill-down capabilities for Simulation in Portfolio Management.

  • Completely redesigned Work Management featuring more collaborative capabilities, Inbox and Kanban views for managing issues, actions, deliverables, risks, etc. and seamlessly moving them around  business cases, projects, products, programs, and portfolios.

  • Fast and easy set up: The Sciforma 7.1 PPM solution is both comprehensive and very fast to install. The complete configuration can be done in a matter of days. It is designed for full scalability, so project teams across the organization and across the globe can instantly tailor it to the methodologies they want to use.

Feedback from customers using early release versions of 7.1 is excellent. "Having been one of the first to use Sciforma 7.1, we're pleased to report that it is very intuitive and easy to use," confirms Amirouche Sellam, PMO Director of Belron-Canada.

Total benefits for PPM users include savings from:

  • Reduced project failure rates;
  • Reduced project cycle times;
  • Reduced costs overruns;
  • Avoiding low/no-value projects;
  • Eliminating PM time spent on low-value tasks.

In fact with Sciforma 7.1, companies running 50 and more projects per year can benefit from millions in savings. (Contact us to discuss your potential ROI based on your specific situation.)

PRICE/AVAILABILITY

Sciforma 7.1 is available for immediate purchase. Please contact a Sciforma representative or reseller for pricing information.

[1] Gartner, Real Project Prioritization Needs Context to Yield Real Results, Analyst(s): Daniel B. Stang , Published: 22 November 2017 ID: G00343401

About Sciforma
Sciforma is one of the largest providers of Portfolio & Project Management software, delivering solutions to quarter million users worldwide since 1982. The company offers flexible and easy-to-use multi-platform project management and project portfolio management software solutions. Businesses that have multiple projects from multiple clients (including internal customers) need to be able to prioritize efforts that will bring the best results to the company. The configurable Sciforma PPM solution provides project managers and executives the ability to analyze investments, plan capacity, manage risks, and control expenses better.  For more information, visit: www.sciforma.com. Follow us on LinkedIn and on Twitter @Sciforma.

Contact:

Valerie Zeller, CMO
vzeller@sciforma.com

Maryse Camelan
maryse@mc3.co
+1 425 985 2121




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sciforma Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum